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We appreciate the comments and
concerns expressed by Dr Sawabata
regarding our article, titled ‘‘Onco-
logic outcomes of segmentectomy
compared with lobectomy for clinical
stage IA lung adenocarcinoma: Pro-
pensity score–matched analysis in a
multicenter study.’’1 We believe any
recurrence in the residual pulmonary
segments after segmentectomy must
be avoided as much as possible, as Sa-
wabata stated. Actually, we experi-
enced 2 recurrences in the residual
segments after segmentectomy in
this study.1 One patient had 2 cm of
pure solid tumor on high-resolution
computed tomography (HRCT). He
underwent resection of left S4þ5 seg-
ments and local recurrence in the sur-
gical stump occurred 6 months after
the operation. The other patient had
2 cm of mixed ground-glass opacity
(GGO) tumor including the majority
of the solid part on HRCT. He under-
went resection of the right S2 segment
and local recurrence developed 24The Journalmonths after the operation. Fortu-
nately, these patients were treated
with completion lobectomy and are
alive well without disease 31 months
and 72 months after the operations,
respectively.
In our study, the independent prog-
nostic factors for local recurrence-free
survival were solid tumor size on
HRCT and maximum standardized
uptake value (SUVmax) on F-18-fluo-
rodeoxyglucose positron emission
tomography/computed tomography
(FDG-PET/CT).1 Therefore, segmen-
tectomy for a tumor that has a large
solid tumor size or a high SUVmax
should be carefully indicated. When
segmentectomy is performed in such
a risky case, taking wide surgical mar-
gins and intraoperative lymph node
assessment using frozen sections are
mandatory. On the other hand, we pre-
viously proposed the N0 criteria of
solid tumor size<0.8 cm or SUVmax
<1.5 for clinical stage IA lung adeno-
carcinoma.2 Patients meeting the N0
criteria can be good candidates for
sublobar resection with sufficient sur-
gical margin including wedge resec-
tion because of little chance to have
pathologic nodal metastasis, for
which we concentrate our attention
on the surgical margin. We also
demonstrated that solid tumor size
on HRCT and SUVmax on FDG-
PET/CT are independent predictors
of pathologic invasiveness, lymph
node metastasis, and prognostic fac-
tors for clinical stage IA lung adeno-
carcinoma.2,3 Optimal surgical
procedure for clinical stage IA lung
adenocarcinoma can be chosen using
solid tumor size on HRCT and
SUVmax on FDG-PET/CT. More-
over, we reported solid tumors
without GGO generally showed worse
pathologic behaviors than mixed tu-
mors with GGO in clinical stage IA
lung adenocarcinoma.4 However, a
solid tumor with low SUVmax can
be a good candidate for segmentec-
tomy because such a tumor has low
malignant potential and shows good
prognosis.2,4of Thoracic and Cardiovascular SurgeWe failed to carry out a subset anal-
ysis comparing segmentectomy with
lobectomy in patients with solid tumor
on HRCT since in only 13 patients we
had performed segmentectomy for
solid tumors. In general, thoracic sur-
geons have tended to choose segmen-
tectomy for a mixed tumor with GGO
in T1 N0 M0 lung adenocarcinoma.
To answer the question ‘‘Is segmen-
tectomy suitable for solid type lung
cancer?’’ we have to await the result
of large phase III trials, CALGB-
140503 in the United States and
JCOG0802/WJOG4607L in Japan.5
We encourage any participants to enroll
patients in these studies.
Yasuhiro Tsutani, MD, PhD
Yoshihiro Miyata, MD, PhD
Morihito Okada, MD, PhD
Department of Surgical Oncology
Hiroshima University
Hiroshima, Japan
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